BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng YC, Lin CL, Hsu WY, Chow WK, Lee SW, Yeh HZ, Chen CC, Kao CH. Association Between Cholangiocarcinoma and Proton Pump Inhibitors Use: A Nested Case-Control Study. Front Pharmacol 2018;9:718. [PMID: 30018559 DOI: 10.3389/fphar.2018.00718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhou W, Chen X, Fan Q, Yu H, Jiang W. Using proton pump inhibitors increases the risk of hepato-biliary-pancreatic cancer. A systematic review and meta-analysis. Front Pharmacol 2022;13:979215. [DOI: 10.3389/fphar.2022.979215] [Reference Citation Analysis]
2 Zeng R, Sha W, Leung FW, Chen H. Letter to the Editor: Proton Pump Inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality? Hepatology 2021;74:3555-6. [PMID: 34351010 DOI: 10.1002/hep.32090] [Reference Citation Analysis]
3 Xiong J, Wang Y, Xu W, Liu Z, Wang H, Zhang Z, Han Y, Yin C, Cao S, Yang Z, Su T, Wei J, Chen G, Jin L. Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case‐control study. Liver Int 2020;40:2848-57. [DOI: 10.1111/liv.14663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]